Skip to content

Direxion Daily S&P Biotech Bull 3X Shares

LABUNYSE ArcaBThis fund multiplies its index's move each day and resets that multiple daily. Because daily returns compound, its long-run return can differ from the headline multiple.

$210.78−21.21 (−9.14%)

At close: Oct 13, 2026, 4:00 PM

Intraday session: down, 79 prints from 231.99 to 210.78. Range 210.50 to 227.31. Use the arrow keys to read each point.215.00220.00225.0010 AM12 PM2 PM4 PM
Expense ratio
0.96%
Fund size
$649M
1Y total return
+117.8%
Yield · Last 12 months
0.39%
Holdings
168
Avg volume · 30D
0.5M sh
NAV per share
$242.82
52W range
low $102.35high $341.93
Launched
Filings
SEC EDGAR

The ETF.net LABU Grade

Based on 4 of 6 pillars

B

Score 64 out of 100

Rank
8 of 31
Six-pillar profile for LABU. Scores out of 100: Cost 73, Risk 46, Mission not scored, Tradability 67, Holdings not scored, Durability 59. Strongest: Cost (73). Weakest: Risk (46). Based on 4 of 6 pillars.

Score 64 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    A73 out of 100
    Rank 6 of 31
  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored
  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    C46 out of 100
    Rank 17 of 30
  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    B67 out of 100
    Rank 7 of 31
  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    Not scored
  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    B59 out of 100
    Rank 10 of 31

Our read on LABU

ETF.net Research

BThree times the daily move of an index of roughly 160 biotech stocks, the corner of the market where one trial readout resets the tape. Direxion's 2015-vintage bull leg, with a bear twin wired to the same benchmark.

Stated mandate

The fund seeks daily investment results, before fees and expenses, equal to 300% of the performance of the S&P Biotechnology Select Industry Index.

Why people hold it

  1. 01Fee is 0.96%, under the typical 3x fund's. Leverage is the pricey shelf in ETF land, and this one sits on the cheaper side of it.
  2. 02The 3x rides a basket of roughly 160 biotech names, not one drug story, so no single approval or rejection owns the day.direxion.com
  3. 03Trading since 2015 and actively traded, and it stands in the upper tier of the leveraged bull funds we cover.
  4. 04A bear twin runs -300% of the same index daily, so the other side of the biotech view uses identical plumbing.direxion.com

Worth knowing

  1. 01The 300% target resets every day. Hold past that and compounding takes the wheel, so multi-day results can land far from 3x the index move over the same stretch.direxion.com
  2. 02Leverage is pointed at one volatile industry, so daily swings arrive tripled in both directions. Position sizing does a lot of work here.
  3. 03Distributions land annually or semiannually at most. This is built as a trading tool, not an income stream.

LABU Holdings

As of Oct 13, 2026
Asset class
Other
Holdings
168
Top-10 weight
78%
Largest holding
Spsibi Swap Asset Leg (Spsibictl)20.2%

Sectors

  • Health Care99.3%
  • Financials0.7%

Geography

  • United States95.36%
  • Ireland1.45%
  • Switzerland1.45%
  • United Kingdom1.25%
  • Netherlands0.48%
The fund’s holdings, weight-ordered — page 1 of 12.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001—Spsibi Swap Asset Leg (Spsibictl)20.18%35,095$422M1
002—Spsibi Swap Asset Leg (Spsibiubl)14.78%25,717$309M1
003—Spsibi Swap Asset Leg (Spsibimll)13.46%23,421$282M1
004—Spsibi Swap Asset Leg (Spsibibcl)10.69%18,598$224M1
005—Spsibi Swap Asset Leg (Spsibijpl)9.06%15,766$190M1
006—Goldman Finl Sq Trsry Inst 5066.19%129,521,051$130M98
007—Spsibi Swap Asset Leg (Spsibibpl)1.22%2,129$26M1
008—Spsibi Swap Asset Leg (Spsibigsl)0.80%1,388$17M1
009—Dreyfus Govt Cash Man Ins0.64%13,479,315$13M108
010MRNAModerna Inc0.56%52,007$12M286
011TWSTTwist Bioscience Corp0.43%56,188$9M125
012NTRANatera Inc0.41%21,351$9M238
013IOVAIovance Biotherapeutics Inc0.38%536,955$8M91
014ABBVAbbVie Inc0.37%28,109$8M522
015UTHRUnited Therapeutics Corp0.36%13,914$8M266

Showing 1–15 of 168 holdings

LABU Performance

Launched May 28, 2015

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

LABU$21,784
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$12,044
Oct 10, 2025 to Oct 12, 2026. LABU $21,784. SPY $12,044. Use the arrow keys to read each point.$7,981$20,919$33,856Oct 2025Apr 2026Oct 2026

Oct 10, 2025 – Oct 12, 2026

Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for LABU. Periods over one year show the average yearly return.
PeriodLABU
Year to date+45.5%
1 month−11.2%
3 months−21.0%
1 year+117.8%
3 yearsper year+55.8%
5 yearsper year−26.1%
10 yearsper year−11.0%

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for LABU
YearReturn barLABU
2026 YTD+45.5%
2025+79.2%
2024−26.0%
2023−13.4%
2022−80.4%
2021−64.2%
2020+74.7%

LABU in the news

Filtered to LABU · Direxion

LABU Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 12, 2026.
0.39%Last 12 months
Payout per share
$0.91Last 12 months
Last payment
$0.91 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Quarterly

Distribution history

2017–2026

One bar per payment. 17 payments from 2017 to 2026 YTD. Dec 13, 2017 $2.66; Jun 19, 2018 $0.39; Sep 25, 2018 $1.91; Dec 27, 2018 $1.92; Mar 19, 2019 $2.19; Jun 25, 2019 $0.74; Sep 24, 2019 $0.22; Dec 23, 2019 $0.11; Jun 21, 2023 $0.18; Sep 19, 2023 $0.04; Dec 21, 2023 $0.21; Mar 19, 2024 $0.16; Jun 25, 2024 $0.15; Mar 25, 2025 $0.11; Jun 24, 2025 $0.22; Sep 23, 2025 $0.10; Dec 23, 2025 $0.91. Use the arrow keys to read each point.2017201820192020202120222023202420252026YTD
Ex-datePay dateAmount per share
Dec 23, 2025Dec 31, 2025$0.91
Sep 23, 2025Sep 30, 2025$0.10
Jun 24, 2025Jul 1, 2025$0.22
Mar 25, 2025Apr 1, 2025$0.11
Jun 25, 2024Jul 2, 2024$0.15
Mar 19, 2024Mar 26, 2024$0.16
Dec 21, 2023Dec 29, 2023$0.21
Sep 19, 2023Sep 26, 2023$0.04
Jun 21, 2023Jun 28, 2023$0.18
Dec 23, 2019Dec 31, 2019$0.11
Sep 24, 2019Oct 1, 2019$0.22
Jun 25, 2019Jul 2, 2019$0.74

LABU Risk

This fund targets a multiple of the daily move of its index and resets daily. Hold it longer than one reset and compounding makes the return diverge from that target. In choppy markets it can lose value even when the index ends flat.

How much the fund’s monthly returns vary, scaled to a year.
79.0%
Annualised · 36 months to Sep 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.84
vs 3-month T-bills · to Sep 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−97.1%
Trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
3.33
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

LABU Cost

Expense ratio0.96%
  • The middle half of 3x Leveraged Long funds
  • Median 0.98%

6 of the 30 3x Leveraged Long funds charge less.

LABU costs $96.00 a year on $10,000. The median 3x Leveraged Long fund costs $98.50.

Other funds in 3x Leveraged Long